Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–24 of 24 results
Advanced filters: Author: Tim F. Greten Clear advanced filters

  • SPP1+ macrophages and CD8 + exhausted T cells are known to crosstalk. Here, the authors discover that extrahepatic tumors facilitate liver metastasis by promoting the formation of an intermediate macrophage population in the liver that inhibits tumor-reactive CD8+ T cell function.

    • Rajiv Trehan
    • Patrick Huang
    • Tim F. Greten
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-20

  • Although cancer genomics is a powerful tool to understand cancer and develop diagnostic tools, the contribution of the microbiome in cancer diagnosis and clinical assessment is much less studied. Elinav, Greten and colleagues provide their respective views on how studying cancer metagenomes could facilitate identification, diagnosis and staging of different tumor types.

    • Lorenz Adlung
    • Eran Elinav
    • Firouzeh Korangy
    News & Views
    Nature Cancer
    Volume: 1, P: 379-381

  • Non-alcoholic fatty liver disease (NAFLD) is shown to promote hepatocellular carcinoma through the generation of linoleic acid, disruption of mitochondrial function and selective loss of CD4+ T cells, leading to impaired anti-tumour immunity.

    • Chi Ma
    • Aparna H. Kesarwala
    • Tim F. Greten
    Research
    Nature
    Volume: 531, P: 253-257

  • Chemotherapy-induced death of colon cancer cells causes ATP release triggering P2X4 to mediate an mTOR-dependent pro-survival program in neighbouring cancer cells, which renders them sensitive to mTOR inhibition.

    • Mark Schmitt
    • Fatih Ceteci
    • Florian R. Greten
    Research
    Nature
    Volume: 612, P: 347-353

  • Drug development in hepatocellular carcinoma had essentially stalled since 2008 when sorafenib was established as the modest standard of care. Now, a positive result in a phase III study evaluating regorafenib challenges us to weigh its clinical significance as well as its real-world benefits and potential harms.

    • Austin G. Duffy
    • Tim F. Greten
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 14, P: 141-142

  • Intratumoral CD8+ T cells commonly display a dysfunctional state, however it remains unclear whether tumor cell metabolism actively promotes T-cell exhaustion. Here, the authors show that the tumor methionine recycling pathway has a central role in promoting T-cell dysfunction in hepatocellular carcinoma, contributing to tumor immune evasion.

    • Man Hsin Hung
    • Joo Sang Lee
    • Xin Wei Wang
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-15

  • A new study provides evidence that platelets exert potent inflammatory effects and play a central part in the progression from simple steatosis to nonalcoholic steatohepatitis. The results from this and other studies raise important questions regarding the role of platelets in the development of hepatocellular carcinoma in individuals with fatty liver disease.

    • Laurence P. Diggs
    • Tim F. Greten
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 16, P: 393-394

  • Tumours produce soluble factors that contribute to the expansion of Gr-1+CD11b+ immature myeloid cells with TGFβ dependent immune suppressive function. Here, the authors show miR-130a and miR-145 target TβRII and reprogram these cells by altering the cytokine microenvironment, improving anti-tumour immunity and inhibiting metastasis in preclinical mouse models.

    • Hiroki Ishii
    • Suman K. Vodnala
    • Li Yang
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-15

  • Multiregion sequencing is needed to better capture the heterogeneity of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Here, the authors analyse HCC and iCCA tumours with multiregion single-cell RNA-seq, revealing cellular dynamics and communication networks with immune cells.

    • Lichun Ma
    • Sophia Heinrich
    • Xin Wei Wang
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-17

  • The availability of regimens containing one or more immune-checkpoint inhibitors (ICIs) has improved the outcomes in patients with advanced-stage hepatocellular carcinoma. However, clinical benefit from these regimens is difficult to predict, indicating the need for novel biomarkers. In this Review, the authors describe the available evidence on biomarkers to guide the use of ICIs in these patients and discuss promising future research directions.

    • Tim F. Greten
    • Augusto Villanueva
    • Xin W. Wang
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 20, P: 780-798

  • In a large multi-cancer cohort, a single liquid biopsy assay enables the detection of four epigenomic modifications, allowing the monitoring of expression of potential drug targets and resistance genes.

    • Sylvan C. Baca
    • Ji-Heui Seo
    • Matthew L. Freedman
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 2737-2741

  • In this Consensus Statement, an international panel of experts present an overview of the latest developments in the field of cholangiocarcinoma. A set of consensus recommendations and research priorities is provided.

    • Jesus M. Banales
    • Pedro M. Rodrigues
    • Victor Lopez-Lopez
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 23, P: 65-96

  • Cholangiocarcinoma is the second most common primary liver cancer, and its incidence is rising worldwide. This Review discusses the immunology of cholangiocarcinoma and provides a comprehensive overview of the preclinical and clinical immunotherapy studies.

    • Tim F. Greten
    • Robert Schwabe
    • Xin W. Wang
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 20, P: 349-365

  • Multiple methods exist to induce liver disease and hepatocellular carcinoma formation in mice. This Review provides an overview of different mouse models of hepatocellular carcinoma, discussing approaches to help choose an appropriate model and highlighting specific concepts for immunotherapy research.

    • Zachary J. Brown
    • Bernd Heinrich
    • Tim F. Greten
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 15, P: 536-554

  • Locoregional therapies, defined as imaging-guided liver tumour-directed procedures, play a leading part in the management of hepatocellular carcinoma. This Review analyses data from randomized and uncontrolled studies reported with ablative and locoregional techniques and examines the expected effects of combinations with systemic treatments, exploring their distinct mechanisms of action.

    • Josep M. Llovet
    • Thierry De Baere
    • Riccardo Lencioni
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 18, P: 293-313

  • In this Review, Llovet and colleagues discuss advances in our knowledge of the pathogenesis and clinical management of nonalcoholic steatohepatitis-related hepatocellular carcinoma. They also discuss future prospects and unmet needs.

    • Josep M. Llovet
    • Catherine E. Willoughby
    • Scott L. Friedman
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 20, P: 487-503